Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMJ Case Rep ; 17(3)2024 Mar 21.
Article in English | MEDLINE | ID: mdl-38514165

ABSTRACT

Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome (SOS) is a severe complication that can occur following haematopoietic stem cell transplant (HSCT) with high-intensity conditioning chemotherapy regimens. Severe VOD/SOS, often characterised by multiorgan failure, is associated with a high mortality rate. This case report details the complex clinical course of a male patient in his mid-20s, recently diagnosed with B cell acute lymphoblastic leukaemia, who underwent allogeneic HSCT. Based on the 2023 European Society for Blood and Marrow Transplantation (EBMT) criteria, the patient developed very severe VOD/SOS, prompting immediate treatment with defibrotide. Unexpectedly, he developed profound hyperammonaemia exceeding 900 µmol/L, leading to encephalopathy and cerebral oedema. Despite aggressive interventions including defibrotide, lactulose, rifampin and haemodialysis, the patient passed away due to cerebral oedema and pulseless electrical activity arrest. We theorise the hyperammonaemia is disproportionate to his hepatic dysfunction and is possibly secondary to an acquired defect of the urea synthesis consistent with idiopathic hyperammonaemia, a rare complication in patients receiving intense conditioning chemotherapy.


Subject(s)
Brain Edema , Hematopoietic Stem Cell Transplantation , Hepatic Veno-Occlusive Disease , Hyperammonemia , Polydeoxyribonucleotides , Humans , Male , Lactulose/therapeutic use , Rifampin/therapeutic use , Hepatic Veno-Occlusive Disease/drug therapy , Hepatic Veno-Occlusive Disease/etiology , Hepatic Veno-Occlusive Disease/diagnosis , Brain Edema/etiology , Hyperammonemia/drug therapy , Hyperammonemia/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Renal Dialysis/adverse effects
2.
Leuk Lymphoma ; 64(14): 2225-2235, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37740588

ABSTRACT

Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients (n = 25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1-21) and ibrutinib 560 mg (days 1-28) of 28-day cycles. The MTD for lenalidomide was 20 mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%). The best ORR was 88%, CR rate was 83%, and median duration of response (DOR) was 36.92 months (95% CI 33.77, 51.37). Responses were seen even in refractory patients or with high-risk features (e.g. blastoid variant, TP53 mutation, Ki-67 > 30%). R2I was safe and tolerable in patients with R/R MCL.


Subject(s)
Lenalidomide , Lymphoma, Mantle-Cell , Piperidines , Rituximab , Adult , Humans , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Lenalidomide/administration & dosage , Lenalidomide/adverse effects , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/pathology , Piperidines/administration & dosage , Piperidines/adverse effects , Piperidines/therapeutic use , Rituximab/administration & dosage , Rituximab/adverse effects , Treatment Outcome , Dose-Response Relationship, Drug , Recurrence
3.
Cancer ; 129(12): 1885-1894, 2023 06 15.
Article in English | MEDLINE | ID: mdl-36951119

ABSTRACT

BACKGROUND: Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studied. The impact of the use of ISAs on ICI efficacy in patients with advanced melanoma was therefore investigated. METHODS: This is a real-world, multicenter, retrospective cohort study of patients with advanced melanoma who received ICIs (n = 370). Overall survival (OS) and time to treatment failure (TTF) from the time of ICI initiation were compared among patients in subgroups of interest by unadjusted and 12-week landmark sensitivity-adjusted analyses. The association of irAEs and their management with OS and TTF were evaluated using univariate and multivariable Cox proportional hazards regression models. RESULTS: Overall, irAEs of any grade and of grade ≥3 occurred in 57% and 23% of patients, respectively. Thirty-seven percent of patients received steroids, and 3% received other ISAs. Median OS was longest among patients receiving both (not reached [NR]), shorter among those receiving only systemic steroids (SSs) (84.2 months; 95% CI, 40.2 months to NR), and shortest among those who did not experience irAEs (10.3 months; 95% CI, 6-20.1 months) (p < .001). Longer OS was significantly associated with the occurrence of irAEs and the use of SSs with or without ISAs upon multivariable-adjusted analysis (p < .001). Similar results were noted with anti-programmed death 1 (PD-1) monotherapy and combination anti-PD-1 plus anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy, and with 12-week landmark sensitivity analysis (p = .01). CONCLUSIONS: These findings in patients with melanoma who were treated with ICIs suggest that the use of SSs or ISAs for the management of irAEs is not associated with inferior disease outcomes, which supports the use of these agents when necessary.


Subject(s)
Immune Checkpoint Inhibitors , Melanoma , Humans , Retrospective Studies , Immune Checkpoint Inhibitors/adverse effects , Immunosuppressive Agents/therapeutic use , Melanoma/drug therapy , Proportional Hazards Models
SELECTION OF CITATIONS
SEARCH DETAIL
...